

April 1, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub: Clarification on news item appeared in newspaper - The Economic Times, dated 01-Apr-2019, titled "Aurobindo Pharma, Lupin Recall Drugs in US Market" and on www.economictimes.indiatimes.com, dated March 31, 2019

Ref : Your emails dated April 1, 2019

This has reference to your above cited emails seeking clarification on the subject matter.

In this regard, we would like to inform you that the current recall is an expansion of the recall initiated in December 2018, for which we have already provided our clarifications on January 28, 2019.

As the value of the products recalled is not material, we have not intimated to stock exchanges.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary

